Epizyme Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Epizyme stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EPZM, but not buy additional shares or sell existing shares.
View analyst ratings for Epizyme or view top-rated stocks.

5 Wall Street research analysts have issued 12-month target prices for Epizyme's shares. Their EPZM stock forecasts range from $1.50 to $6.00. On average, they expect Epizyme's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 136.5% from the stock's current price.
View analysts' price targets for Epizyme or view top-rated stocks among Wall Street analysts.

Epizyme's stock was trading at $2.50 on January 1st, 2022. Since then, EPZM stock has decreased by 40.8% and is now trading at $1.48.
View the best growth stocks for 2022 here.

Epizyme is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Epizyme.

Epizyme, Inc. (NASDAQ:EPZM) announced its quarterly earnings data on Tuesday, May, 10th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.04. The biopharmaceutical company earned $8.70 million during the quarter, compared to analysts' expectations of $10.86 million. Epizyme had a negative trailing twelve-month return on equity of 2,459.33% and a negative net margin of 614.08%. During the same quarter in the previous year, the firm earned ($0.69) EPS.
View Epizyme's earnings history.

Some companies that are related to Epizyme include Procaps Group (PROC), Avid Bioservices (CDMO), MannKind (MNKD), Crinetics Pharmaceuticals (CRNX), ImmunoGen (IMGN), Veru (VERU), Merus (MRUS), I-Mab (IMAB), Aclaris Therapeutics (ACRS), Enanta Pharmaceuticals (ENTA), Deciphera Pharmaceuticals (DCPH), uniQure (QURE), Rocket Pharmaceuticals (RCKT), ADVANZ PHARMA (CXRXF) and Morphic (MORF).
View all of EPZM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Pfizer (PFE), Micron Technology (MU), Novavax (NVAX), CRISPR Therapeutics (CRSP), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD) and Dynavax Technologies (DVAX).

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Epizyme's stock is owned by many different institutional and retail investors. Top institutional investors include Primecap Management Co. CA (9.44%), BlackRock Inc. (6.55%), Vanguard Group Inc. (4.53%), Rock Springs Capital Management LP (4.41%), Palo Alto Investors LP (4.12%) and Platinum Investment Management Ltd. (4.01%). Company insiders that own Epizyme stock include Carl Goldfischer, David M Mott, Jeffery Kutok, Joseph Beaulieu, Matthew Ros, Pablo G Legorreta, Paolo Tombesi, Robert B Bazemore, Robert B Bazemore and Shefali Agarwal.
View institutional ownership trends for Epizyme.

EPZM stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Graham Capital Management L.P., BNP Paribas Arbitrage SA, State Board of Administration of Florida Retirement System, and Group One Trading L.P.. Company insiders that have sold Epizyme company stock in the last two years include Jeffery Kutok, Joseph Beaulieu, Matthew Ros, Paolo Tombesi, Robert B Bazemore, and Shefali Agarwal.
View insider buying and selling activity for Epizyme or view top insider-selling stocks.

EPZM stock was purchased by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd., Rock Springs Capital Management LP, BlackRock Inc., Assenagon Asset Management S.A., Goldman Sachs Group Inc., Bank of America Corp DE, Woodline Partners LP, and Vanguard Group Inc.. Company insiders that have bought Epizyme stock in the last two years include Carl Goldfischer, David M Mott, and Pablo G Legorreta.
View insider buying and selling activity for Epizyme or or view top insider-buying stocks.

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EPZM stock can currently be purchased for approximately $1.48.

Epizyme (NASDAQ:EPZM) has a market capitalization of $244.02 million and generates $37.43 million in revenue each year. The biopharmaceutical company earns $-251.12 million in net income (profit) each year or ($2.14) on an earnings per share basis.

Epizyme employs 250 workers across the globe.

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for Epizyme is www.epizyme.com. The biopharmaceutical company can be reached via phone at (617) 229-5872, via email at [email protected], or via fax at 617-349-0707.